

Obesity

Pharmacotherapy for obesity

Volume 46, No.7, 2017 (<http://www.racgp.org.au/afp/2017/july/>) Pages 472-477

Phong Ching Lee

John Dixon

Background

Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants. Pharmacotherapy can be a useful adjunct to lifestyle intervention in effecting and maintaining clinically meaningful weight loss.

Objective/s

The aim of this article is to discuss the role of pharmacotherapy in obesity management. The efficacy, side effects and contraindications of available weight-loss medications are reviewed.

Discussion

Long-term pharmacotherapy options, which can be effective in providing moderate weight loss, are available to treat obesity. Pharma-cotherapy should be considered an adjunct to lifestyle intervention in those with a body mass index (BMI) >30 kg/m², or in those with a BMI of 27–30 kg/m² and obesity-related complications. Safety and efficacy should be monitored closely on commencement, and the medication should be discontinued if there are safety or tolerability issues, or if <5% weight loss is observed after three to four months.

Obesity is a serious, chronic, relapsing disease of energy regulation with strong genetic and early-life environmental determinants.^{1,2} For the majority of patients, following an exemplary diet and exercise recommendations provide only modest weight loss that is difficult to sustain.³ Similarly to the treatment of other chronic diseases, we need tools beyond lifestyle interventions to deliver better health outcomes.

Pharmacotherapy currently plays a major role in managing diseases of dysregulation, including hypertension, type 2 diabetes mellitus (T2DM), dyslipidaemia and cancer. Indeed, we have a responsibility to provide appropriate care for these common complications of obesity. The low uptake of all effective therapies beyond lifestyle interventions for weight management would be unacceptable for other chronic diseases. We need a more proactive approach to treat obesity, especially for those who are clinically severely obese, with a focus on psychological, physical and metabolic complications. Weight loss is the most logical, broadly effective and commonly sought outcome by patients with obesity.

Who should be considered for pharmacotherapy?

The goals in managing chronic disease are patient-centric, with an informed patient being able to make choices to improve health outcomes. For patients who are obese, the benefits of high-quality diet, physical activity and behavioural change do extend well beyond what may be frustratingly small changes on the scales and, as such, lifestyle management remains the foundation for improved health outcomes.

Pharmacotherapy for weight management should be seen as an adjunct to lifestyle intervention, just as it is for managing hypertension, diabetes and cardiovascular disease, not as a replacement. Drug therapy acts physiologically by altering energy regulation, usually by reducing appetite, providing satiation with a smaller meal, and more prolonged satiety following the small meal. Naturally, all medications have their risks and side effects and, as clinicians, we are always weighing the risks and benefits of therapy with the risks and severity of the disease.

Body mass index (BMI), when adjusted for age and sex, is generally an excellent measure of percentage body fatness in the population.^{4,5} BMI is an accepted measure to screen for the health risks of obesity and provide cut-off points as indication for more intensive therapies. Weight-loss pharmacotherapy should be considered for patients with a BMI >30 kg/m², or those with a BMI of 27–30 kg/m² with obesity-related complications.^{6–8} Lower BMI thresholds (BMI >27 kg/m², or BMI >25 kg/m² with obesity-related complications) should be considered in Aboriginal and Torres Strait Islander and Asian populations. Orlistat,

phentermine and liraglutide have been approved by the Therapeutic Goods Administration (TGA) for the treatment of obesity in Australia, and topiramate is an effective off-label agent that is currently available for the management of epilepsy and migraine.

Weight-loss pharmacotherapy

Phentermine

Phentermine is a sympathomimetic agent that suppresses appetite. Analysis of randomised controlled trials (RCTs) indicates weight loss at six months of 3.6 kg, compared with placebo.⁹ More recently, phentermine 15 mg was shown to induce a weight loss of 4.5 kg over placebo after six months of therapy (Table 1).¹⁰ Phentermine is available in a slow-release resin preparation in doses of 15, 30 and 40 mg, and given as a single daily dose early in the day. Starting with 15 mg and grading up as needed reduces early cessation because of predictable, generally mild, sympathomimetic effects of dry mouth, insomnia, agitation, constipation and tachycardia. Using the lowest effective dose also reduces risks of side effects.

Given the effects of phentermine on the cardiovascular system, it should not be used in patients with a history of cardiovascular disease. Other contraindications include anxiety disorders, hyperthyroidism, history of drug or alcohol abuse or dependence, concomitant treatment with monoamine oxidase inhibitors, pregnancy and breastfeeding. It should be used with caution in patients with hypertension, history of cardiac arrhythmias, or seizures.¹¹ Careful monitoring of blood pressure should be performed while the patient is on phentermine.

Phentermine has been the most commonly used weight-loss management medication in Australia and the US for decades.¹² Historically, it has been approved as a short-term therapy, but for treating obesity, a chronic condition, this is illogical. Phentermine has now been studied over a two-year period in combination with topiramate,¹³ and the combination is approved for long-term use by the US Food and Drug Administration (FDA).⁷ The same combination has also been studied in Australia.¹⁴ In addition, the addiction potential of long-term phentermine use is low,¹⁵ and there is minimal evidence that long-term phentermine monotherapy is associated with serious side effects.⁷ The TGA product label recommends careful evaluation before and at three months of use. Further use is at the discretion of the practitioner in conjunction with the patient. It may be reasonable to prescribe phentermine long term, provided the following criteria are met:^{7,16}

- low-to-intermediate cardiovascular risk with no evidence of serious cardiovascular disease
- no serious psychiatric disease or history of substance abuse
- no clinically significant increase in pulse or blood pressure while taking phentermine
- close monitoring – monthly during dose escalation and at least every three months thereafter
- efficacy–safety stopping rule (described below) is followed.

Orlistat

Orlistat inhibits pancreatic and gastric lipases and thus reduces absorption of dietary fat. It is the only approved weight-loss medication that does not work primarily by suppressing appetite, and has a relatively good long-term safety record. Taken in a dose of 120 mg three times a day with meals, approximately 30% of oral fat intake is excreted in the stool. A mean weight loss of 2.9–3.4% is observed after one year of orlistat.⁷ Side effects are due to fat malabsorption and include steatorrhoea, oily spotting, flatulence with discharge, faecal incontinence, fat-soluble vitamin deficiencies and calcium oxalate kidney stones.

Gastrointestinal side effects, the main reason for discontinuing therapy, can be reduced by adhering to a low-fat diet and increasing dietary fibre. In individuals with T2DM, improvements in glycated haemoglobin (HbA1c) of 0.4% were also observed with orlistat, compared with controls.¹⁷ The XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study found that orlistat reduces the incidence of T2DM by 37% over four years when added to lifestyle therapy in patients who are obese.¹⁸

Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) agonist initially used to treat T2DM, and controls hyperglycaemia without causing hypoglycaemia or weight gain. Its side effect profile of decreased appetite, reduced energy intake and subsequent weight loss has led to its more recent approval as a weight management drug. A large RCT has found that liraglutide 3 mg leads to 5.6 kg (5.4%) weight loss over placebo after one year.¹⁹ There were corresponding improvements in cardiometabolic risk factors, including inflammatory markers, glycaemic parameters, blood pressure and lipid levels.

Liraglutide was recently approved in Australia for weight management as an adjunct to diet and physical activity. It can be given independently of meals, as a subcutaneous injection into the abdomen, thigh or upper arms. The starting dose of liraglutide is 0.6 mg once daily. The dose should be increased to 3 mg in increments of 0.6 mg, with intervals of at least one week to improve gastrointestinal tolerability. Lower doses can be continued if effective when there are gastrointestinal tolerance issues with higher doses.

Common side effects of liraglutide are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation and dyspepsia, which can be mitigated by gradual dose escalation. Most gastrointestinal symptoms are mild to moderate, transient and diminish within days or weeks with continued treatment. Liraglutide-induced weight loss is associated with an increased incidence of symptomatic gallstones and, more rarely, pancreatitis. Patients should be warned about these conditions. Liraglutide should not be used in those with severe renal insufficiency (including end-stage renal failure), hepatic insufficiency, pregnancy, past history of pancreatitis or major depression, or psychiatric disorder.

Currently, liraglutide appears to have the strongest evidence base for cardiovascular safety, although most studies looked at its effect as an antidiabetic agent, using a lower dose. Liraglutide may be well suited as a weight-loss agent for those at high cardiovascular risk, or with glucose intolerance such as T2DM or pre-diabetes. Drawbacks include high costs (about \$380/month in Australia) and gastrointestinal side effects that may limit its use.

Off-label pharmacotherapy

Several medications that are not approved by the TGA for weight loss are used off-label in Australia to treat individuals with obesity when other medications are ineffective or contraindicated. Thorough knowledge of side effects, precautions and contraindications of these medications is essential and we caution against their prescription by practitioners without expertise in obesity management. Risks and benefits of off-label use should also be discussed with the patient and clearly documented.

Topiramate

Topiramate is an anticonvulsant used to treat seizures and for migraine prophylaxis. It is also used off-label to treat obesity because of the side effect of weight loss. Several meta-analyses have estimated that 3.4–5.0 kg weight loss can be expected with topiramate monotherapy.^{20,21} Effective doses range between 25 and 100 mg daily. Side effects are dose-dependent and commonly include paraesthesia, dry mouth, constipation, altered taste sensation, insomnia and dizziness.²² Dose-related cognitive side effects include psychomotor slowing, decreased concentration and attention, memory impairment and language difficulties.²² Rare but serious side effects include closed-angle glaucoma and increase in suicidal thoughts or ideations. Topiramate should not be used in pregnancy or in individuals with a history of glaucoma or renal stones.

Table 1. Pharmacotherapy used in obesity management in Australia⁷

Drug	Starting dose	Available doses	Weight loss versus placebo (% or kg)	Side effects	Contraindications
Phentermine	15 mg	15, 30, 40 mg	3.6–4.5 kg at six months	Dry mouth, insomnia, agitation, constipation, and tachycardia	Severe hypertension, cardiovascular disease, glaucoma, history of drug or alcohol abuse, monoamine oxidase inhibitors, selective serotonin reuptake inhibitor use, pregnancy
Orlistat	120 mg TDS	120 mg	2.9–3.4% at one year	Steatorrhea, oily spotting, flatulence with	Pregnancy

discharge,
faecal
incontinence,
fat-soluble
vitamin
malabsorption

Liraglutide	0.6 mg	0.6–3.0 mg	5.4% at one year	Nausea, vomiting, diarrhoea, constipation Rare: Pancreatitis, cholecystitis	Severe renal or hepatic insufficiency, pregnancy, past history of pancreatitis and major depression or psychiatric disorder
-------------	--------	------------	------------------	--	---

Off-label pharmacotherapy (not approved by Therapeutic Goods Administration for weight loss)

Topiramate	12.5 mg mane	25, 50, 100 mg	3.4–5.0 kg	Paraesthesia, dry mouth, constipation, altered taste sensation, insomnia, dizziness, cognitive effects Rare: Closed angle glaucoma, depression or suicidal ideation	Glaucoma, renal stones, pregnancy (if used for weight loss)
------------	--------------	----------------	------------	--	---

Phentermine (Phe)/topiramate (Top)	Phe: 15 mg mane Top: 12.5 mg mane	Phe: 15 mg Top: 12.5, 25, 50, 100 mg	5.0–6.6% at one year	Side effects of phentermine and topiramate	Contraindications to phentermine or topiramate
------------------------------------	--------------------------------------	---	----------------------	--	--

Table 2. Common antidiabetic drugs and their effects on body weight^{7,32}

Produces weight loss (mean weight loss)	Are weight neutral	Causes weight gain (mean weight gain)
Metformin (0.6–1.2 kg)	Acarbose	Insulin (1.5–3 kg)
Glucagon-like peptide-1 (GLP-1) receptor agonists (eg exenatide, liraglutide; 1.8–2.5 kg)	Dipeptidyl peptidase-4 (DPP-4) inhibitors (eg sitagliptin, linagliptin, vildagliptin)	Sulfonylureas (eg glipizide, gliclazide, tolbutamide; 2 kg)
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (eg canagliflozin, dapagliflozin, empagliflozin; 1.8–2.7 kg)		Metiglinides (eg repaglinide; 1.8 kg)
		Thiazolidinediones (eg pioglitazone; 2.6 kg)

Phentermine/topiramate combination

Fixed-dose combinations of phentermine/topiramate are approved in the US to treat obesity. Phase 3 RCTs found weight reduction of 5.1–10.5% and improvement in metabolic parameters with the combination (Table 1).^{23,24} An Australian study examined the combination of phentermine 15 mg and topiramate 25 mg for weight maintenance after initial weight loss with very low energy diets (VLEDs).¹⁴ Forty per cent of patients in the study could not tolerate the combination, primarily because of side effects from topiramate. In the cohort that tolerated the combination, further weight loss of 5% (6.7 kg) was observed after a mean duration of 22 months.

Other medications

Two other weight loss medications approved in the US but not available in Australia include a naltrexone/bupropion combination and lorcaserin. The combination of an opioid antagonist (naltrexone) and a dopamine and noradrenaline re-uptake inhibitor (bupropion) has been shown to provide average weight loss of 4.8% after one year.²⁵ Common side effects include nausea, vomiting, headache, dizziness and dry mouth.

Lorcaserin, a selective 5-hydroxytryptamine (5-HT) 2C receptor agonist, suppresses appetite, with expected weight loss of 3.6% at one year.²⁶ Common side effects include upper respiratory tract infections, headache, dizziness, nasopharyngitis and nausea. Unlike non-selective 5-HT receptor agonists (eg fenfluramine), the incidence of cardiac valvulopathy was not increased with lorcaserin.²⁶

Efficacy–safety stopping rule

On commencement of weight-loss medications, patients should be reviewed closely for the first three months (four months for medications such as liraglutide and topiramate that require gradual dose escalation) to assess safety, tolerability and efficacy. The medication should be stopped immediately should any safety or significant tolerability issues arise. There is significant variability in individual responses, with regard to weight loss, to these medications. Weight loss at 12–16 weeks predicts later weight loss at one year and beyond.¹² Sustained weight loss of 5% leads to significant improvement in obesity-related comorbidities.⁶ Therefore, if the patient's response is insufficient (weight loss <5% at three to four months) despite optimisation of adherence and dose, the medication should be stopped, as the long-term benefits are likely to be outweighed by the risks and costs of treatment (Case). This sound approach has some exceptions, as pharmacotherapy is often best used to maintain weight loss following intensive dietary therapy (eg VLED), placement of intragastric balloons or even after bariatric surgery.^{11,27} In these instances, satiety and limiting weight regain would be an indication for continued therapy. In addition, if one agent is not performing adequately, adding a second agent would provide an alternative clinical approach, with an additional 12–16 week assessment made.

Pharmacotherapy for patients with obesity and T2DM

There is strong evidence to suggest that obesity management is beneficial for the treatment of T2DM.⁸ Table 2 summarises the common antidiabetic agents used, based on their effects on body weight. In the absence of contraindications, metformin should be used as first-line therapy for T2DM as it is safe, effective, inexpensive, and may reduce cardiovascular events and death.²⁸ If combination therapy is needed, or if metformin is contraindicated, the weight profile of second-line medications should be carefully considered. Whenever possible, medications chosen should promote weight loss or be weight neutral.

Several recent cardiovascular outcome trials have reported positive data on patients with T2DM at high cardiovascular risk. The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial has found that empagliflozin, a sodium–glucose co-transporter 2 (SGLT-2) inhibitor, significantly decreased cardiovascular events by 14% (10.5% versus 12.1% with placebo) and cardiovascular death by 38% (3.7% versus 5.9% with placebo) after 3.1 years.²⁹ More recently, the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial found that liraglutide reduced cardiovascular events by 13% (13.0% versus 14.9% with placebo) and cardiovascular death by 22% (4.7% versus 6.0% with placebo) after median follow-up of 3.8 years.³⁰ The cardiovascular safety and favourable weight profile of these antidiabetic agents provide an attractive option for individuals with obesity and T2DM, especially for those at high cardiovascular risk.

Pharmacotherapy for long-term use

Despite the efficacy of pharmacotherapy in producing weight loss, drugs used for weight loss are often discontinued. Reasons for cessation of therapy include costs, concerns regarding side effects and the perception that the medication is no longer necessary as a sufficient amount of weight is lost.³¹ On the contrary, if therapy is well tolerated and effective, it should be continued, similarly to the way antihypertensive and antidiabetic medications are continued even after blood pressure or glycaemic control is at target. This reflects the fact that obesity is a chronic disease that requires sustained treatment, with pharmacotherapy playing an important role in promoting long-term weight maintenance and limiting weight regain.

Perhaps one of the reasons contributing to the treatment inertia in commencing or continuing pharmacotherapy to treat obesity is the concern regarding long-term adverse effects, especially cardiovascular and mental health safety. The unease is understandable given the safety issues that have led to the withdrawal of anti-obesity agents in the past (eg fenfluramine, sibutramine, rimonabant). To date, there have not been any safety signals that have emerged to suggest that any of the currently available medications are not suitable for use in the long term. Large cardiovascular outcome studies are currently being conducted for the newer medications (eg phentermine/topiramate combination, lorcaserin, naltrexone/bupropion) and should provide further long-term safety data as these become available.

Conclusion

Understanding of the various weight-loss medications available, indications, common side effects and limitations in specific patient populations allows general practitioners (GPs) to decide if, and which, pharmacotherapy is appropriate when managing patients with obesity. If used, these medications should be stopped if there are safety or tolerability concerns, or if clinically meaningful weight loss (>5%) is not achieved. Similarly, if the medication produces satisfactory weight loss and is well tolerated, it should not be discontinued empirically. Rather, medications reinforce lifestyle management and play a useful role in long-term management of obesity. By widening the repertoire in their toolbox, GPs can increase the probability of identifying a combination of treatment options that can help their patients manage overweight and obesity.

Case

Sally, 34 years of age, had been attending your practice for many years. She had a past medical history of obesity, hypertension, dyslipidaemia and polycystic ovary syndrome. Her medications included amlodipine 10 mg daily, perindopril 8 mg daily and atorvastatin 40 mg daily.

Sally had previously tried to lose weight with lifestyle interventions, including VLEDs and structured exercise programs, and achieved modest weight loss of 5 kg, which was not sustainable. She was single and her job involved administrative work in a mostly sedentary environment. On clinical examination, her weight was 98 kg (BMI = 37.8 kg/m²) and blood pressure was 145/80 mmHg. She was keen to lose weight to improve her health and overall wellbeing, and wished to explore other options to aid with her efforts to lose weight.

Modest weight loss of 5–10% could result in significant clinical benefit and improvement of Sally's many obesity-related complications; unfortunately, the weight loss achieved with lifestyle modifications was not durable. Adjunctive therapies with pharmacotherapy or surgery would be appropriate considerations in this case.

Phentermine was considered but not chosen given her hypertension. Liraglutide was commenced, with a starting dose of 0.6 mg, and gradually escalated to 1.8 mg daily. Sally was unable to tolerate higher doses because of gastrointestinal side effects. The medication improved her adherence to caloric restriction, and she achieved weight loss of 5 kg.

Two years later, Sally's weight had increased to 108 kg (BMI = 41.7 kg/m²). She discontinued liraglutide six months ago because of cost constraints. Sally expressed interest in bariatric surgery, and underwent an uneventful laparoscopic sleeve gastrectomy with no early surgical complications. Appropriate multivitamin, multimineral, calcium and vitamin D supplementation were prescribed.

Three months after surgery, Sally lost 20 kg (18.5% of her body weight). Her antihypertensive medications were decreased, and her blood pressure was 124/76 mmHg on perindopril 4 mg daily. Nutritional screening did not reveal any micronutrient deficiencies, and Sally was counselled on the importance of adherence to long-term postoperative follow-up to ensure a safe and successful outcome.

Authors

Phong Ching Lee MBChB, MRCP (UK), Consultant Endocrinologist, Obesity and Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore. lee.phong.ching@singhealth.com.sg (<mailto:lee.phong.ching@singhealth.com.sg>)

John Dixon MBBS, PhD, FRACGP, FRCP (Edin), NHMRC Senior Research Fellow; Head of Clinical Obesity Research, Baker Heart and Diabetes Institute; Adjunct Professor, Primary Care Research Unit, Monash University, Melbourne, Vic

Competing interests and funding: John Dixon has provided consultancy services to Apollo Endosurgery, Covidien, Nestle Health Science, Bariatric Advantage, I-Nova, and Novo-Nordisk. John Dixon acknowledges the support of the NHMRC through a senior research fellowship. Phong Ching Lee has no competing interests to declare.

Provenance and peer review: Commissioned, externally peer reviewed

References

1. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. *Nature* 2006;443(7109):289–95. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443\(7109\):289–95.](http://www.ncbi.nlm.nih.gov/pubmed?term=Morton+GJ,+Cummings+DE,+Baskin+DG,+Barsh+GS,+Schwartz+MW.+Central+nervous+system+control+of+food+intake+and+body+weight.+Nature+2006;443(7109):289-95.))
2. Buhmann H, le Roux CW, Bueter M. The gut-brain axis in obesity. *Best Pract Res Clin Gastroenterol* 2014;28(4):559–71. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Buhmann H, le Roux CW, Bueter M. The gut-brain axis in obesity. Best Pract Res Clin Gastroenterol 2014;28\(4\):559–71.](http://www.ncbi.nlm.nih.gov/pubmed?term=Buhmann+H,+le+Roux+CW,+Bueter+M.+The+gut-brain+axis+in+obesity.+Best+Pract+Res+Clin+Gastroenterol+2014;28(4):559-71.))
3. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. *N Engl J Med* 2011;365(17):1597–604. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365\(17\):1597–604.](http://www.ncbi.nlm.nih.gov/pubmed?term=Sumithran+P,+Prendergast+LA,+Delbridge+E,+et+al.+Long-term+persistence+of+hormonal+adaptations+to+weight+loss.+N+Engl+J+Med+2011;365(17):1597-604.))
4. Dixon JB, Lambert EA, Grima M, Rice T, Lambert GW, Straznicki NE. Fat-free mass loss generated with weight loss in overweight and obese adults: What may we expect? *Diabetes Obes Metab* 2015;17(1):91–93. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Dixon JB, Lambert EA, Grima M, Rice T, Lambert GW, Straznicki NE. Fat-free mass loss generated with weight loss in overweight and obese adults: What may we expect? Diabetes Obes Metab 2015;17\(1\):91–93.](http://www.ncbi.nlm.nih.gov/pubmed?term=Dixon+JB,+Lambert+EA,+Grima+M,+Rice+T,+Lambert+GW,+Straznicki+NE.+Fat-free+mass+loss+generated+with+weight+loss+in+overweight+and+obese+adults:+What+may+we+expect?+Diabetes+Obes+Metab+2015;17(1):91-93.))
5. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? *Am J Epidemiol* 1996;143(3):228–39. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996;143\(3\):228–39.](http://www.ncbi.nlm.nih.gov/pubmed?term=Gallagher+D,+Visser+M,+Sepulveda+D,+Pierson+RN,+Harris+T,+Heymsfield+SB.+How+useful+is+body+mass+index+for+comparison+of+body+fatness+across+age,+sex,+and+ethnic+groups?+Am+J+Epidemiol+1996;143(3):228-39.))
6. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation* 2014;129(25 Suppl 2):S102–38. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129\(25 Suppl 2\):S102–38.](http://www.ncbi.nlm.nih.gov/pubmed?term=Jensen+MD,+Ryan+DH,+Apovian+CM,+et+al.+2013+AHA/ACC/TOS+guideline+for+the+management+of+overweight+and+obesity+in+adults:+A+report+of+the+American+College+of+Cardiology/American+Heart+Association+Task+Force+on+Practice+Guidelines+and+The+Obesity+Society.+Circulation+2014;129(25+Suppl+2):S102-38.))
7. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: An endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2015;100(2):342–62. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: An endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100\(2\):342–62.](http://www.ncbi.nlm.nih.gov/pubmed?term=Apovian+CM,+Aronne+LJ,+Bessesen+DH,+et+al.+Pharmacological+management+of+obesity:+An+endocrine+Society+clinical+practice+guideline.+J+Clin+Endocrinol+Metab+2015;100(2):342-62.))
8. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Melbourne: NHMRC, 2013. Available at www.nhmrc.gov.au/guidelines/publications/n57. (<http://www.nhmrc.gov.au/guidelines/publications/n57>) [Accessed 1 May 2017].
9. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. *Ann Intern Med* 2005;142(7):532–46. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 2005;142\(7\):532–46.](http://www.ncbi.nlm.nih.gov/pubmed?term=Li+Z,+Maglione+M,+Tu+W,+et+al.+Meta-analysis:+Pharmacologic+treatment+of+obesity.+Ann+Intern+Med+2005;142(7):532-46.))
10. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. *Obesity* 2013;21(11):2163–71. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate](http://www.ncbi.nlm.nih.gov/pubmed?term=Aronne+LJ,+Wadden+TA,+Peterson+C,+Winslow+D,+Odeh+S,+Gadde+KM.+Evaluation+of+phentermine+and+topiramate+versus+phentermine/topiramate+extended-release+in+obese+adults.+Obesity+2013;21(11):2163-71.)

[versus phentermine/topiramate extended-release in obese adults. Obesity 2013;21\(11\):2163–71.](#))

11. Apovian CM, Garvey WT, Ryan DH. Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. *Obesity* 2015;23 Suppl 2:S1–26. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Apovian CM, Garvey WT, Ryan DH. Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity 2015;23 Suppl 2:S1–26.\)](#)
12. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: A systematic and clinical review. *JAMA* 2014;311(1):74–86. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: A systematic and clinical review. JAMA 2014;311\(1\):74–86.\)](#)
13. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. *Am J Clin Nutr* 2012;95(2):297–308. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults \(SEQUEL\): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95\(2\):297–308.\)](#)
14. Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Proietto J. Combination phentermine and topiramate for weight maintenance: The first Australian experience. *Med J Aust* 2014;201(4):224–26. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Proietto J. Combination phentermine and topiramate for weight maintenance: The first Australian experience. Med J Aust 2014;201\(4\):224–26.\)](#)
15. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. *Int J Obes* 2014;38(2):292–98. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes 2014;38\(2\):292–98.\)](#)
16. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: A new drug combination for the treatment of obesity. *J Hypertens* 2014;32(6):1178–88. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: A new drug combination for the treatment of obesity. J Hypertens 2014;32\(6\):1178–88.\)](#)
17. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. *Diabetes Obes Metab* 2009;11(4):361–71. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009;11\(4\):361–71.\)](#)
18. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27(1):155–61. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects \(XENDOS\) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27\(1\):155–61.\)](#)
19. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med* 2015;373(1):11–22. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373\(1\):11–22.\)](#)
20. Paravattil B, Wilby KJ, Turgeon R. Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Res Clin Pract* 2016;114:9–14. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Paravattil B, Wilby KJ, Turgeon R. Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016;114:9–14.\)](#)
21. Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: A meta-analysis of randomized controlled trials. *Obes Rev* 2011;12(5):e338–47. [Search PubMed \(http://www.ncbi.nlm.nih.gov/pubmed?term=Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: A meta-analysis of](#)


[randomized controlled trials. Obes Rev 2011;12\(5\):e338–47.](#))

22. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. *Diabetes Metab Syndr Obes* 2013;6:131–39. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Shin JH, Gadde KM. Clinical utility of phentermine/topiramate \(Qsymia\) combination for the treatment of obesity. Diabetes Metab Syndr. Obes 2013;6:131–39.](http://www.ncbi.nlm.nih.gov/pubmed?term=Shin+JH,+Gadde+KM.+Clinical+utility+of+phentermine/topiramate+(Qsymia)+combination+for+the+treatment+of+obesity.+Diabetes+Metab+Syndr.+Obes+2013;6:131–39.))
23. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). *Obesity* 2012;20(2):330–42. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial \(EQUIP\). Obesity 2012;20\(2\):330–42.](http://www.ncbi.nlm.nih.gov/pubmed?term=Allison+DB,+Gadde+KM,+Garvey+WT,+et+al.+Controlled-release+phentermine/topiramate+in+severely+obese+adults:+A+randomized+controlled+trial+(EQUIP).+Obesity+2012;20(2):330–42.))
24. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377(9774):1341–52. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults \(CONQUER\): A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377\(9774\):1341–52.](http://www.ncbi.nlm.nih.gov/pubmed?term=Gadde+KM,+Allison+DB,+Ryan+DH,+et+al.+Effects+of+low-dose,+controlled-release,+phentermine+plus+topiramate+combination+on+weight+and+associated+comorbidities+in+overweight+and+obese+adults+(CONQUER):+A+randomised,+placebo-controlled,+phase+3+trial.+Lancet+2011;377(9774):1341–52.))
25. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2010;376(9741):595–605. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults \(COR-1\): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376\(9741\):595–605.](http://www.ncbi.nlm.nih.gov/pubmed?term=Greenway+FL,+Fujioka+K,+Plodkowski+RA,+et+al.+Effect+of+naltrexone+plus+bupropion+on+weight+loss+in+overweight+and+obese+adults+(COR-1):+A+multicentre,+randomised,+double-blind,+placebo-controlled,+phase+3+trial.+Lancet+2010;376(9741):595–605.))
26. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. *N Engl J Med* 2010;363(3):245–56. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363\(3\):245–56.](http://www.ncbi.nlm.nih.gov/pubmed?term=Smith+SR,+Weissman+NJ,+Anderson+CM,+et+al.+Multicenter,+placebo-controlled+trial+of+lorcaserin+for+weight+management.+N+Engl+J+Med+2010;363(3):245–56.))
27. Farina MG, Baratta R, Nigro A, et al. Intra-gastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. *Obes Surg* 2012;22(4):565–71. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Farina MG, Baratta R, Nigro A, et al. Intra-gastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 2012;22\(4\):565–71.](http://www.ncbi.nlm.nih.gov/pubmed?term=Farina+MG,+Baratta+R,+Nigro+A,+et+al.+Intra-gastric+balloon+in+association+with+lifestyle+and/or+pharmacotherapy+in+the+long-term+management+of+obesity.+Obes+Surg+2012;22(4):565–71.))
28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359(15):1577–89. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359\(15\):1577–89.](http://www.ncbi.nlm.nih.gov/pubmed?term=Holman+RR,+Paul+SK,+Bethel+MA,+Matthews+DR,+Neil+HA.+10-year+follow-up+of+intensive+glucose+control+in+type+2+diabetes.+N+Engl+J+Med+2008;359(15):1577–89.))
29. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373(22):2117–28. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373\(22\):2117–28.](http://www.ncbi.nlm.nih.gov/pubmed?term=Zinman+B,+Wanner+C,+Lachin+JM,+et+al.+Empagliflozin,+cardiovascular+outcomes,+and+mortality+in+type+2+diabetes.+N+Engl+J+Med+2015;373(22):2117–28.))
30. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;375(4):311–22. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375\(4\):311–22.](http://www.ncbi.nlm.nih.gov/pubmed?term=Marso+SP,+Daniels+GH,+Brown-Frandsen+K,+et+al.+Liraglutide+and+cardiovascular+outcomes+in+type+2+diabetes.+N+Engl+J+Med+2016;375(4):311–22.))
31. Jain P, Rostbjerg AS, Haase CL, Rhee NA. Weight loss experiences and willingness to intervention with pharmacotherapy among obese and very obese Danish people. *Phys Sportsmed* 2016;44(3):201–07. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=Jain P, Rostbjerg AS, Haase CL, Rhee NA. Weight loss experiences and willingness to intervention with pharmacotherapy among obese and very obese Danish people. Phys Sportsmed 2016;44\(3\):201–07.](http://www.ncbi.nlm.nih.gov/pubmed?term=Jain+P,+Rostbjerg+AS,+Haase+CL,+Rhee+NA.+Weight+loss+experiences+and+willingness+to+intervention+with+pharmacotherapy+among+obese+and+very+obese+Danish+people.+Phys+Sportsmed+2016;44(3):201–07.))
32. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A systematic review and mixed-treatment comparison meta-analysis. *Open Med*. 2011;5(1):e35–48. [Search PubMed](#) ([http://www.ncbi.nlm.nih.gov/pubmed?term=McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5\(1\):e35–48.](http://www.ncbi.nlm.nih.gov/pubmed?term=McIntosh+B,+Cameron+C,+Singh+SR,+et+al.+Second-line+therapy+in+patients+with+type+2+diabetes+inadequately+controlled+with+metformin+monotherapy:+A+systematic+review+and+mixed-treatment+comparison+meta-analysis.+Open+Med.+2011;5(1):e35–48.))

Correspondence afp@racgp.org.au (<mailto:afp@racgp.org.au>)

Downloads

[? Help with downloads](#)

 [AFP Focus Pharmacotherapy 2017 \(PDF 359KB\)](#)
(</download/Documents/AFP/2017/July/AFP-Focus-Pharmacotherapy-2017.pdf>)



Australian Family Physician (incorporating Annals of General Practice) is published by The Royal Australian College of General Practitioners, 100 Wellington Parade, East Melbourne, Victoria 3002, Australia
afp@racgp.org.au (<mailto:afp@racgp.org.au>)

© The Royal Australian College of General Practitioners 2016
All rights reserved. Requests for permission to reprint articles must be sent to permissions@racgp.org.au (<mailto:permissions@racgp.org.au>).

The views expressed by the authors of articles in Australian Family Physician are their own and not necessarily those of the publisher or the editorial staff, and must not be quoted as such. Every care is taken to reproduce articles accurately, but the publisher accepts no responsibility for errors, omissions or inaccuracies contained therein or for the consequences of any action taken by any person as a result of anything contained in this publication. The content of any advertising or promotional material contained within, or mailed with, Australian Family Physician is not necessarily endorsed by the publisher.

[Privacy \(http://www.racgp.org.au/usage/privacy/\)](http://www.racgp.org.au/usage/privacy/) | [Terms of use \(http://www.racgp.org.au/usage/terms/\)](http://www.racgp.org.au/usage/terms/)



RACGP

Healthy Profession.
Healthy Australia.